CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 85 enrolled
Drug / intervention
MERIVA® Tablets +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04705220
NCT04705220N/ACompleted
CompareCT.gov

Effect of Nutritional Supplementation With Turmeric on the Cognitive Performance of Subjects With Metabolic Syndrome

Indena S.p.A·interventional·Posted Jan 12, 2021·Updated Feb 2, 2026

In Brief

A clinical study evaluating MERIVA® Tablets and Placebo Tablets for Mild Cognitive Impairment. Completed, enrolled 85 participants across 1 site.

Detailed Summary

The EPICURO study aims to demonstrate the beneficial effects of a 6-month dietary supplementation with an improved bioavailable turmeric (MERIVA®) on inflammatory, oxidative and metabolic parameters together with cognitive performance, potentially resulting in the reduction of the risk of cognitive decline in subjects, male and female, with Metabolic Syndrome. The results obtained will provide novel insights on MERIVA® for improving the prevention of age-related cognitive decline and Alzheimer's disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMild Cognitive Impairment
CountriesItaly
CollaboratorsIstituto Superiore di Sanità, Sintesi Research Srl

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedJan 12, 2021
Enrollment StartApr 8, 2022
Primary CompletionOct 16, 2025
Study CompletionDec 19, 2025
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 5.5 years ago

Interventions

MERIVA® Tabletsdietary

The treatment corresponds to 1 g / day of experimental product (corresponding to about 200 mg of curcuminoids).

Placebo Tabletsother

The composition of placebo includes the same components of the treatment tablets, except for the active substance.